Highlights,Elanco Animal Health reported a miss in earnings, with EPS falling short of expectations.,Analysts adjusted their ...

In a big win for House Speaker Mike Johnson, House Republicans got their budget plan through the chamber on a 217-215 vote.

Elanco Animal Health Incorporated has entered into an agreement with South Dakota-based Medgene to leverage the company's ...

Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has entered into an agreement with South Dakota-based ...

Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health’s Fourth Quarter 2024 Earnings Conference ...

Stifel analyst Jonathan Block lowered the firm’s price target on Elanco (ELAN) to $15 from $16 and keeps a Buy rating on the shares. While the ...

Barclays lowered the firm’s price target on Elanco (ELAN) to $19 from $20 and keeps an Overweight rating on the shares. The firm sees a “solid ...

Elanco Animal Health Incorporated (NYSE:ELAN – Get Free Report) shares reached a new 52-week low during mid-day trading on Tuesday after the company announced weaker than expected quarterly earnings.

A novel parasite protection therapy from Elanco Animal Health received FDA approval in October 2024, and was recently made available on the market with a launch at the 2025 Veterinary Meeting & Expo ...

Elanco Animal Health announced the establishment of an agreement with Medgene, a South Dakota-based biotechnology company, to utilize its advanced vaccine platform technology (baculovirus derived ...

Elanco's Q4 revenue reached $1.02 billion, topping estimates, but EPS missed forecasts. 2025 guidance lags consensus as currency headwinds pose a $110 million challenge.

Welcome to Elanco Animal Health fourth quarter 2024 earnings conference call. At this time, all lines have been placed on ...